June 5, 2026
The Cooper Companies (COO): Reading Past the Legal Noise
First a note from America’s Gold Company
Dear Reader,
JPMorgan. Goldman. Morgan Stanley. In total, 21 banks are brokering the SpaceX IPO.
They will collect billions in fees on a deal that was done before you heard about it.
By the time you can buy a single share, the people who built the system will have already made 30 times their money.
That’s not a surprise. That’s the plan.
But here’s what they’re not telling you…
While every financial newsletter in America is hyping SpaceX, the world’s central banks have been buying gold, 850 tonnes last year alone.
Not shares. Not funds. Not pie in the sky. Actual physical gold. The one asset that exists entirely outside the system.
Ask yourself why the institutions that created the paper money system keep moving their own reserves into the one thing that doesn’t depend on it.
Then ask yourself why your retirement is still 100% inside the system they’re quietly stepping away from.
We put together a free 2026 Gold Guide on exactly what they know and what you can do about it.
It costs nothing. Takes 30 seconds to request.
The insiders already made their move.
Now it’s your turn.
⚡ Trading Cheat Sheet — COO
- Ticker: COO (Nasdaq)
- Today’s Move: +6% intraday; peak of +6.8% flagged by momentum scanners
- Q2 Revenue: $1.082B — beat consensus of ~$1.065B; up 8% YoY (5% organic)
- Non-GAAP EPS: $1.21 vs. $1.107 est. — up 26% YoY; 10th consecutive beat
- GAAP EPS: $(0.40) — distorted by $271.6M litigation charge (excluded from non-GAAP)
- The Legal Charge: $324.1M accrued settlement from Dec. 2023 embryo culture media recall at CooperSurgical; offset by $52.5M insurance recovery; 95%+ of claimants settled
- CooperVision (CVI): $723.5M revenue, +8% reported (+4% organic); toric/multifocal lenses +11%
- CooperSurgical (CSI): $358.0M revenue, +8% reported (+6% organic); fertility +13%
- FY2026 Guidance: Revenue $4.285B–$4.321B; Non-GAAP EPS $4.58–$4.66
- Free Cash Flow: $96.4M in Q2; LT target reaffirmed at $2.2B+ through FY2028
- Watch: Asia Pacific CVI declined 6% — restructuring underway; APAC stabilization expected by Q4
- Tariff exposure: $22M baked into guidance; potential $15M refund upside if realized
STOP SELLING On Fridays…
Every late Friday afternoon like clockwork, traders close their positions for the week. But not this veteran trader.
He’s loading up knowing breaking after-hours news is about to drop that’ll have you desperate all weekend and scrambling to buy back shares on Monday morning at twice… even triple what you sold them for.
All the while he gets to bank as much $16,159 or more just for holding shares over the weekend.
Here’s the thing about legal overhangs — they create a window. Not always, but sometimes the noise gives you cover to buy into a business that was quietly running well the entire time.
That’s the Cooper Companies setup this week. The GAAP number looks ugly — $(0.40) diluted EPS — but that’s almost entirely the result of a $271.6 million net pre-tax charge tied to settlements on a December 2023 embryo culture media recall at CooperSurgical. Resolved. More than 95% of claimants covered. Partially backstopped by insurance. The kind of thing that, once it clears the books, stops being a conversation.
Strip that out and the underlying business posted its tenth consecutive non-GAAP earnings beat.
What’s interesting here is where the growth is actually coming from. CooperVision’s toric and multifocal lens category grew 11% on a reported basis — that’s a premium, specialty product line, not commodity volume. The daily silicone hydrogel segment remains the backbone, and the Americas and EMEA are both holding organic growth above 6%. The fertility segment at CooperSurgical jumped 13% reported, 10% organic. That kind of number in a macro environment that’s been uneven across med-tech deserves more attention than it’s getting.
Slight tangent, but it matters: management flagged AI-led inventory optimization as one reason CooperVision production was trimmed, contributing to a margin headwind in Q3. That reads more like discipline than deterioration — companies that actively right-size ahead of demand signals usually don’t end up with the inventory impairment problems that bite harder later.
Trump’s last desperate move could change everything
Trump’s approval is at 36%. Midterms are seven months away. He needs a move that changes everything overnight.
He has one. It doesn’t require Congress. It could add over $1 trillion to the government’s balance sheet and potentially make a large number of everyday Americans very wealthy.
A president used this same move once before in 1934. It created generational fortunes. A free report explains what it is and how to get positioned before he plays it.
The one real thing worth watching is Asia Pacific. A 6% organic decline in CVI across Japan, China, and Korea is not nothing. New leadership is in, and management is calling for sequential stabilization by Q4. Maybe. But APAC has a habit of being the last shoe to drop in med-tech recoveries, and that region carries enough scale that it could dampen the next couple of quarters even if the core thesis holds.
The broader read here isn’t just about COO. It’s about how the market is repricing legacy legal liability in healthcare hardware — once the settlement structure becomes visible and the insurance offset is confirmed, institutional buyers tend to move. That’s what today’s tape is showing. The question is whether the follow-through holds into the next quarter, or whether the revised guidance range — which came in a touch tighter on CooperVision revenue — becomes the new friction point.
For now, the underlying product demand story is intact. The litigation chapter is effectively closed. Whether that’s already in the price at these levels — that’s the part that stays open.
— Editorial Desk
